The grades of four Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
This week, Incyte Corp. (NASDAQ:INCY) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. In Portfolio Grader’s specific subcategories of Earnings Momentum, Earnings Revisions, and Sales Growth, INCY also gets A’s. For more information, get Portfolio Grader’s complete analysis of INCY stock.
This week, Seattle Genetics‘ (NASDAQ:SGEN) ratings are up from a C last week to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
Amarin‘s (NASDAQ:AMRN) ratings are looking better this week, moving up to a B from last week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. For more information, get Portfolio Grader’s complete analysis of AMRN stock.
This week, 3SBio (NASDAQ:SSRX) pushes up from a C to a B rating. 3SBio is a biotechnology company that engages in the research and development, manufacture, and distribution of pharmaceutical products in the Peoples Republic of China. For more information, get Portfolio Grader’s complete analysis of SSRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.